Charles Schwab Investment Management Inc. Grows Stock Holdings in AnaptysBio, Inc. (NASDAQ:ANAB)

Charles Schwab Investment Management Inc. raised its position in AnaptysBio, Inc. (NASDAQ:ANAB) by 3.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 160,321 shares of the biotechnology company’s stock after purchasing an additional 5,043 shares during the period. Charles Schwab Investment Management Inc.’s holdings in AnaptysBio were worth $5,371,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Rhumbline Advisers lifted its holdings in shares of AnaptysBio by 1.8% during the 2nd quarter. Rhumbline Advisers now owns 29,715 shares of the biotechnology company’s stock worth $745,000 after acquiring an additional 525 shares during the last quarter. Algert Global LLC raised its position in AnaptysBio by 11.8% in the 2nd quarter. Algert Global LLC now owns 10,178 shares of the biotechnology company’s stock worth $255,000 after purchasing an additional 1,078 shares during the period. nVerses Capital LLC raised its position in AnaptysBio by 700.0% in the 3rd quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock worth $54,000 after purchasing an additional 1,400 shares during the period. Values First Advisors Inc. purchased a new position in AnaptysBio in the 3rd quarter worth $49,000. Finally, China Universal Asset Management Co. Ltd. raised its position in AnaptysBio by 81.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company’s stock worth $195,000 after purchasing an additional 2,600 shares during the period.

AnaptysBio Price Performance

NASDAQ:ANAB opened at $15.02 on Friday. AnaptysBio, Inc. has a one year low of $14.20 and a one year high of $41.31. The company’s 50-day simple moving average is $25.93 and its 200 day simple moving average is $29.48. The firm has a market capitalization of $457.04 million, a P/E ratio of -2.47 and a beta of -0.11.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.72) by $0.58. The firm had revenue of $30.02 million for the quarter, compared to the consensus estimate of $7.92 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. On average, equities research analysts expect that AnaptysBio, Inc. will post -6.02 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on ANAB. BTIG Research cut shares of AnaptysBio from a “buy” rating to a “neutral” rating in a research report on Monday, December 2nd. Wedbush restated an “outperform” rating and issued a $40.00 price objective (down previously from $42.00) on shares of AnaptysBio in a research report on Wednesday. Guggenheim decreased their price objective on shares of AnaptysBio from $90.00 to $36.00 and set a “buy” rating on the stock in a research report on Thursday. Truist Financial boosted their price objective on shares of AnaptysBio from $20.00 to $30.00 and gave the company a “hold” rating in a research report on Thursday, August 15th. Finally, Wells Fargo & Company decreased their price objective on shares of AnaptysBio from $56.00 to $40.00 and set an “overweight” rating on the stock in a research report on Thursday. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, AnaptysBio presently has a consensus rating of “Moderate Buy” and an average target price of $45.09.

Insider Activity at AnaptysBio

In other AnaptysBio news, CFO Dennis Mulroy sold 12,220 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $39.91, for a total transaction of $487,700.20. Following the completion of the sale, the chief financial officer now directly owns 4,744 shares of the company’s stock, valued at approximately $189,333.04. This represents a 72.03 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Paul F. Lizzul sold 1,500 shares of the company’s stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $38.67, for a total transaction of $58,005.00. Following the sale, the insider now directly owns 15,398 shares of the company’s stock, valued at approximately $595,440.66. This represents a 8.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 22,440 shares of company stock worth $892,936 over the last quarter. Company insiders own 33.70% of the company’s stock.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.